Page 25 - Libro de Ponencias Congres SEHH-SETH 2017

according to the WHO classi cation based on prognostic signi cance of morphological features in patients with refractory anemia according to the FAB classi cation. Leukemia. 2007;21(4):678-86.
21. Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D, et al Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011;365(15):1384-95.
22. Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, et al. Fre- quent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478(7367):64-9.
23. Malcovati L, Karimi M, Papaemmanuil E, Ambaglio I, Jädersten M, Jansson M, et al. SF3B1 mutation identi es a distinct subset of myelodysplastic syn- drome with ring sideroblasts. Blood. 2015;126(2):233-41.
24. Greenberg PL, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. Internation- al scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079-88.
25. Greenberg PL, Tuechler H, Schanz J, Sanz G, García-Manero G, Solé F, et al. Revised international prognostic scoring system for myelodysplastic syn- dromes. Blood. 2012;120:2454-65.
26. Ogata K, Satoh C, Hyodo H, Tamura H, Dan K, Yoshida Y. Association between phenotypic features of blasts and the blast percentage in bone marrow of patients with myelodysplastic syndromes. Leuk Res. 2004;28(11):1171-5.
27. Arenillas L,Calvo X,Luño E,Senent L,Alonso E,Ramos F,et al.Considering Bone Marrow Blasts From Nonerythroid Cellularity Improves the Prognostic Evalua- tion of Myelodysplastic Syndromes. J Clin Oncol. 2016;34(27):3284-92.
28. Calvo X,Arenillas L,Luño E,Senent L,Arnan M,Ramos F,et al.Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future classi cations of myelodysplastic syndromes. Mod Pathol. 2016;29(12):1541-51.
ow cytometric immunophenotyping of normal, reactive and malignant leu-
kocytes. Leukemia. 2012;26(9):1908-75.
33. Kalina T, Flores-Montero J, Lecrevisse Q, Pedreira CE, van der Velden VH, No-
vakova M, et al. Quality assessment program for EuroFlow protocols: sum- mary results of four-year (2010-2013) quality assurance rounds. Cytometry A. 2015;87(2):145-56.
34. Porwit A, van de Loosdrecht AA, Bettelheim P, Brodersen LE, Burbury K, Cre- mers E, et al. Revisiting guidelines for integration of ow cytometry results in the WHO classi cation of myelodysplastic syndromes-proposal from the International/European Leukemia Net Working Group for Flow Cytometry in MDS. Leukemia. 2014;28(9):1793-8.
35. Van de Loosdrecht AA, Westers TM, Westra AH, Dräger AM, van der Velden VH, Ossenkoppele GJ. Identi cation of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by ow cytometry. Blood. 2008;111(3):1067-77.
35. Ogata K, Kishikawa Y, Satoh C,Tamura H, Dan K, Hayashi A. Diagnostic applica- tion of ow cytometric characteristics of CD34+ cells in low-grade myelodys- plastic syndromes. Blood. 2006;108(3):1037-44.
36. Ogata K, Della Porta MG, Malcovati L, Picone C, Yokose N, Matsuda A, et al. Diagnostic utility of ow cytometry in low-grade myelodysplastic syndromes: a prospective validation study. Haematologica. 2009;94(8):1066-74.
37. Van de Loosdrecht AA, Westers TM, Westra AH, Dräger AM, van der Velden VH, Ossenkoppele GJ. Identi cation of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by ow cytometry. Blood. 2008;111(3):1067-77.
38. Wells DA, Benesch M, Loken MR, Vallejo C, Myerson D, Leisenring WM, et al. Myeloid and monocytic dyspoiesis as determined by ow cytometric scor- ing in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood. 2003;102(1):394-
29. Calvo X, Arenillas L, Luño E, Senent L, Arnan M, Ramos F, et al. Enumerating
Bone Marrow Blasts from Nonerythroid Cellularity Improves Outcome Pre- 403.
diction in Myelodysplastic Syndromes and Permits a Better De nition of the Intermediate Risk Category of the Revised International Prognostic Scoring System (IPSS-R). Am J Hematol. 2017;92(7):614-21.
30. Stetler-Stevenson M, Arthur DC, Jabbour N, Xie XY, Molldrem J, Barrett AJ, et al. Diagnostic utility of ow cytometric immunophenotyping in myelodysplastic syndrome. Blood. 2001;98(4):979-87.
31. Westers TM, Ireland R, Kern W, Alhan C, Balleisen JS, Bettelheim P, et al. Stan- dardization of ow cytometry in myelodysplastic syndromes: a report from an international consortium and the European Leukemia Net Working Group. Leukemia. 2012;26(7):1730-41.
32. Van Dongen JJ, Lhermitte L, Böttcher S, Almeida J, van der Velden VH, Flores- Montero J, et al. EuroFlow antibody panels for standardized n-dimensional
39. Scott BL, Wells DA, Loken MR, Myerson D, Leisenring WM, Deeg HJ. Valida- tion of a ow cytometric scoring system as a prognostic indicator for post- transplantation outcome in patients with myelodysplastic syndrome. Blood. 2008;112(7):2681-6.
40. Alhan C,WestersTM,Cremers EM,Cali C,Witte BI,Ossenkoppele GJ,et al.The myelodysplastic syndromes ow cytometric score: a three-parameter prog- nostic ow cytometric scoring system. Leukemia. 2016;30(3):658-65.
41. Matarraz S, López A, Barrena S, Fernández C, Jensen E, Flores J, et al. The immunophenotype of different immature, myeloid and B-cell lineage- committed CD34+ hematopoietic cells allows discrimination between normal/reactive and myelodysplastic syndrome precursors. Leukemia. 2008;22(6):1175-83.
LIX Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia / Ponencias
25